Skip to main content

Table 1 Summary of AXL immunostaining in patient LPS samples

From: AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

Histology Patients (n) Samplesc (n) Positive for AXL immunostain
Patients (%) (n = 83) Samples (%) (n = 104)
NF 12 12 0 (0) 0 (0)
LPS (Total) 83 104 23 (27.7) 27 (26.0)
LPS subtype     
 WDLPS     
  Extremity 3 3 - -
  Retroperitoneum 31 43 7 (22.6) 7 (16.3)
Total 34 46 7 (20.6) 7 (15.2)
 DDLPS     
  Extremity 1 1 - -
  Retroperitoneum 17 18 4 (23.5) 4 (22.2)
Total 18 19 4 (22.2) 4 (21.1)
 PLS     
  Extremity 23 29 10 (43.5) 11 (37.9)
  Retroperitoneum 2 2 - -
  Other a,b 7 8 2 (28.6) 3 (37.5)
Total 31 39 12 (37.5) 14 (35.9)
  1. aOne patient with PLS had a primary tumor in the extremity as well as a metastatic lesion in the lung which was included on the TMA. Therefore, the total number of PLS patients is 31, not 32
  2. bOther locations include lung (n = 4 patients, 5 samples) and chest/back (n = 3 patients, 3 samples)
  3. cSeveral patients had multiple tumor samples included on the TMA